Nkarta (NKTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with voting available online until June 9, 2026.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of two directors to serve until the 2029 annual meeting: Ali Behbahani, M.D., M.B.A., and Zachary Scheiner, Ph.D.
Ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Advisory approval of executive compensation as disclosed in the proxy statement.
Advisory vote on the frequency of future say-on-pay votes, with the board recommending every 1 year.
Proxies may vote on other business that arises at the meeting.
Board of directors and corporate governance
Board recommends the election of two directors for multi-year terms, ensuring continuity in governance.
Latest events from Nkarta
- Q2 2026 net loss was $40.4M; $243.2M in cash expected to fund operations into 2029.NKTX
Q2 2026 - CD19-directed CAR-NK therapy advances in autoimmune trials, with data and strong cash runway ahead.NKTX
H.C. Wainwright 27th Annual Global Investment Conference - Allogeneic NK cell therapy trials advance in autoimmune diseases, with data updates expected this year.NKTX
TD Cowen 46th Annual Health Care Conference - Upcoming 2026 data will shape the future of CAR-NK therapy in autoimmune diseases.NKTX
H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - All proposals were approved, with director elections and executive compensation votes passing.NKTX
AGM 2026 - Off-the-shelf NK cell therapy targets autoimmune diseases with promising safety and efficacy.NKTX
Corporate presentation - Net loss narrowed in Q1 2026 as clinical trials advanced and cash runway extends into 2029.NKTX
Q1 2026 - Board recommends approval of all proxy proposals, with strong governance and compensation oversight.NKTX
Proxy filing - Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway.NKTX
25th Annual Needham Virtual Healthcare Conference